Migraine prevention with a supraorbital transcutaneous stimulator
A randomized controlled trial
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:

Article Information
- Received April 23, 2012
- Accepted October 4, 2012
- First Published February 6, 2013.
Article Versions
- Previous version (February 6, 2013 - 13:01).
- You are viewing the most recent version of this article.
Author Disclosures
- Jean Schoenen, MD, PhD,
- Bart Vandersmissen, MD,
- Sandrine Jeangette, MD,
- Luc Herroelen, MD,
- Michel Vandenheede, MD,
- Pascale Gérard, Phy and
- Delphine Magis, MD, PhD
- Jean Schoenen, MD, PhD,
- St Jude Medical USA, - Allergan USA - ATI USA
NONE
ATI Redwood Cal USA - travel expenses to congress
- Acta Neurologica Belgica, Editor-in-chief, 2009-ongoing- Cephalalgia, Associate Editor, 2005-ongoing- Journal of Head and Pain, Editorial Advisory Board Member, 2008-ongoing
Use of thioctic acid as a preventive treatment in migraine
Wall & Melzack's Textbook of Pain. Elsevier. 2001- Handbook of Pain Management. Elsevier. 2009- Wall & Melzack's Textbook of Pain. Elsevier. 2010- Comorbidity in Migraine. Wiley & Blackwell. 2011- Multidisciplinary Management of Migraine. Jones & Bartlett Learning. 2012
NONE
ATI Redwood Cal USA
NONE
NONE
NONE
- Medtronic USA - Cyberonics USA.
National Fund for Scientific Research - Belgium. Research Convention 3.4650.09, 2009-2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bart Vandersmissen, MD,
(1) Allergan
NONE
NONE
(1)acta neurologica belgica, associate editor, since 2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sandrine Jeangette, MD,
NONE
NONE
Invited by Janssen-Cilag to attend the “migraine trust” annual meeting in London-UK: Travel expenses and accommodation.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Luc Herroelen, MD,
Served on the scientific advisory board for Allergan (2010-2012).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michel Vandenheede, MD,
(1) Allergan - USA
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Pascale Gérard, Phy and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Delphine Magis, MD, PhD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Headache Research Unit (J.S., P.G., D.M.), Department of Neurology & GIGA–Neurosciences, Liège University, Citadelle Hospital, Liege; Department of Neurology (B.V.), CHU Erasme, University of Brussels & Clinique de l'Europe, Brussels; Department of Neurology (S.J.), CHU Charleroi, Charleroi; Department of Neurology (L.H.), AZ Gasthuisberg, Catholic University of Leuven, Leuven; and CHC Espérance Liège (M.V.), Montegnee, Belgium.
- Correspondence to Dr. Schoenen: jschoenen{at}ulg.ac.be
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
- Addendum to "Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial"
- Jean E Schoenen, Co-Director Headache Research Unit
Published October 01, 2015 - Re:Do we need a method to pre-operatively predict the efficacy of STS?
- Jean Schoenen, Professor
- Jean Schoenen, Liege,BE; Bart Vandersmissen, Brussels, BE; Sandrine Jeangette, Charleroi,BE; Luc Herroelen, Leuven, BE; Michel Vandenheede, Liege, BE; Pascale Gerard, Liege, BE; Delphine Magis, Liege, BE.
Published May 15, 2013 - Do we need a method to pre-operatively predict the efficacy of STS?
- Fan-gang Meng, Vice Director
- Jian-guo Zhang
Published March 07, 2013
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.